CorMedix (CRMD): Assessing Valuation After a Strong Multi-Year Share Price Run [Yahoo! Finance]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Yahoo! Finance
This performance has put fresh attention on this kidney infection focused biotech. See our latest analysis for CorMedix. With the share price now at $12.19 and a 30 day share price return of 24.13 percent feeding into a 48.30 percent year to date share price gain, the move looks more like gathering momentum rather than a one off spike. This is especially the case when you factor in the hefty 221.64 percent three year total shareholder return. If CorMedix has you rethinking your healthcare exposure, this could be a good moment to explore other potential movers across healthcare stocks and see what else fits your strategy. Yet with CorMedix still trading at a steep discount to analyst targets despite powerful multi year gains, are investors looking at an underappreciated growth story, or has the market already priced in the next leg higher? With CorMedix last closing at $12.19 against a narrative fair value of $19, the spread points to a sizeable upside case that hinges on spe
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath? [Yahoo! Finance]Yahoo! Finance
- Is It Too Late to Consider CorMedix After DefenCath Progress and Strong Price Gains? [Yahoo! Finance]Yahoo! Finance
- CorMedix (NASDAQ:CRMD) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.MarketBeat
- CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCathGlobeNewswire
- 5 High Earnings Yield Value Picks Ahead of Key Economic Reports [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 11/12/25 - Beat
CRMD
Sec Filings
- 12/19/25 - Form 4
- 12/18/25 - Form 144
- 12/11/25 - Form 4
- CRMD's page on the SEC website